MARKET

COLL

COLL

Collegium Pharmaceutical Inc
NASDAQ
21.45
-0.21
-0.97%
Opening 15:19 11/28 EST
OPEN
21.52
PREV CLOSE
21.66
HIGH
21.99
LOW
21.43
VOLUME
53.29K
TURNOVER
836.77K
52 WEEK HIGH
22.89
52 WEEK LOW
14.04
MARKET CAP
720.12M
P/E (TTM)
-17.0049
1D
5D
1M
3M
1Y
5Y
Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference
STOUGHTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual...
GlobeNewswire · 6d ago
--Needham Adjusts Price Target on Collegium Pharmaceutical to $34 From $36, Maintains Buy Rating
--Needham Adjusts Price Target on Collegium Pharmaceutical to $34 From $36, Maintains Buy Rating
MT Newswires · 11/04 11:02
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $34
Benzinga · 11/04 10:57
BRIEF-Collegium Reports Third Quarter 2022 Financial Results
Reuters · 11/03 22:29
Collegium Pharmaceutical (COLL) Lags Q3 Earnings Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -9.84% and 2.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 22:15
Collegium Pharmaceutical Q3 EPS $0.01 Beats $(0.13) Estimate, Sales $127.01M Beat $124.45M Estimate
Benzinga · 11/03 20:36
Collegium Pharmaceutical GAAP EPS of $0.01 beats by $0.15, revenue of $127M beats by $2.64M
Seekingalpha · 11/03 20:18
-- Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q3 EPS $1.10
-- Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q3 EPS $1.10
MT Newswires · 11/03 16:08
More
About COLL
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company focused on pain management. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

Webull offers kinds of Collegium Pharmaceutical Inc stock information, including NASDAQ:COLL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COLL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading COLL stock methods without spending real money on the virtual paper trading platform.